Harmony Biosciences

At Harmony Biosciences, we are dedicated to developing and delivering innovative therapies for people living with rare neurological diseases who have unmet medical needs. Our commitment to pursue innovative and novel treatments extends beyond clinical endpoints. We aim to address real-world patient needs with potential first-in-class and best-in-class therapies. We believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we nurture. Harmony Biosciences’ culture is defined by our core values – keeping patients at the heart of all we do, acting with integrity and ethics, working with a one-team attitude, leading with the science as we identify clinical possibilities, and delivering excellence.

Company Ownership: Public Stock Symbol: HRMY

LEADERSHIP
CEO: Jeff M. Dayno, MD

630 W. Germantown Pike, Suite 215
Plymouth Meeting, PA 19462

Tel: 484-539-9800

Visit website

Email Us

NEWS

Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration

Neuroscience

Harmony’s Dravet Drug Halves Monthly Seizures in Late-Stage Study

The Phase III, open-label extension study suggests EPX-100 has a “positive” risk/benefit profile for the treatment of Dravet syndrome, analysts at H.C. Wainwright & Co. said Tuesday.

December 3, 2025

2 min read

Tristan Manalac

Pictured: Businessmen shaking hands after closing a deal

Deals

Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout

Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba Pharmaceuticals’ cannabinoid therapies for neuropsychiatric disorders.

August 15, 2023

2 min read

Tristan Manalac

Pictured: Scales of justice swing in the air/court

Policy

Scorpion Stings Harmony with Citizen’s Petition Threat for Sleepiness Drug

Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.

March 29, 2023

3 min read

Lisa Munger and Tristan Manalac

Drug Development

Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

A roundup of last week’s top clinical trial updates and news.

April 29, 2022

10 min read

Mark Terry

Business

A New $550 Million Life Sciences Venture Capital Fund is in Town

venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.

June 3, 2021

3 min read

Mark Terry

Drug Development

Rare Disease Companies Unite to Advocate for Life-Changing Therapies

The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.

May 13, 2021

4 min read

Kate Goodwin

Drug Development

Clinical Catch-Up: December 14-18

Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.

December 18, 2020

13 min read

Mark Terry

FDA

FDA Approves First Non-Controlled Substance Treatment for Narcolepsy

The FDA approved Wakix for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

August 15, 2019

2 min read

Alex Keown

Drug Development

Harmony Biosciences Makes Headway on Narcolepsy Drug Involving Histamine

For type 1 narcolepsy, this sleep-wake instability is linked to low levels of hypocretin, also called orexin. Hypocretin is a neurotransmitter produced in the hypothalamus and has a significant role in wakefulness and regulating rapid eye movement (REM) sleep. But Harmony Biosciences has found another link, this one to histamine.

June 21, 2018

4 min read

Mark Terry

JOBS